AngioDynamics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- James C. Clemmer
- Full Time Employees
- 632
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 14 Plaza Drive Latham NY United States of America 12110
- IPO Date
- Jun 1, 2004
- CIK
- 0001275187
- Website
- angiodynamics.com
- Similar Companies
- Business
- AngioDynamics, Inc. designs, manufactures, and markets innovative medical devices for minimally invasive, image-guided treatments of peripheral vascular disease, oncology, and cardiovascular conditions; its core products span oncology offerings including the NanoKnife System for precise tumor ablation, Habib 4X Bipolar Resection Device, and IsoLoc Endorectal Balloon; venous therapies such as VenaCure EVLT 1470 Pro Laser System and procedure packs; vascular interventions featuring the Auryon Atherectomy System, AngioVac and AlphaVac mechanical thrombectomy systems, and ports; and diagnostic tools like the Model 1500X RF Generator and Alatus balloon. The company, founded in 1988 and headquartered in Latham, New York, operates globally with facilities in the United States, Europe, and Australasia, serving interventional radiologists, nephrologists, surgeons, and healthcare providers treating critical limb ischemia, pulmonary embolism, and cancer patients. In fiscal 2026 first quarter, AngioDynamics reported strong growth including 20.1% increase in Auryon sales to $16.5 million, 41.2% rise in mechanical thrombectomy sales to $11.3 million driven by AngioVac and AlphaVac, and 26.7% growth in NanoKnife sales to $6.4 million; it enrolled the first patient in the AMBITION BTK trial for Auryon in below-the-knee lesions and the RECOVER-AV trial for AlphaVac in intermediate-risk pulmonary embolism across Europe, Canada, and Hong Kong.
Company News
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics Stock Is Falling Thursday: What's Going On?
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
Why AngioDynamics Crashed Today
AngioDynamics Q1 Earnings Call Highlights
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates
AngioDynamics (NASDAQ:ANGO) Announces FY 2027 Earnings Guidance
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
32,900 Shares in AngioDynamics, Inc. $ANGO Acquired by Canada Pension Plan Investment Board
AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus